Takeover14 Jul 2025 07:01
I think considering the long-term interest of the company and growth plans as well as difficulties in raising capital in the AIM markets, I think it is in the best interest of shareholders IMO to sell the company for around 25-35million to any of the following companies:
| **Company** | **Market Cap** | **Primary Test** | **Profile** |
| ----------------------------- | -------------- | ---------------- | ------------------------------------- |
| **Abbott Laboratories** | \~\$230β―B | PSA | Global diagnostic & healthcare leader |
| **Danaher (Beckman Coulter)** | \~\$146β―B | PHI | Major life-sciences diagnostics group |
| **Siemens Healthineers** | \~\$61β―B | Imaging, DIags | Leading medical imaging/diagnostics |
| **Beckman Coulter** | \~\$2.8β―B | PHI production | Subsidiary under Danaher |
| **OPKO Health** | \~\$1.07β―B | 4Kscore test | Small-cap diagnostics & pharma firm |
it is pocket money for these companies, Testing with a standard PSA test is 55% accurate.. where as Episwitch PSE Detect prostate cancer likelihood from blood with 94% accuracy. It is game changing and seems like a no brainer to bring in at scale Episwitch tests as standard for pre-screening.
I think 25-35mil is baseline fair value at this stage, considering it will need to inject further capital to grow the business. I believe the OBD has already raised, invested burned at least 50mil.. so it would be good if shareholders at least recoup some of their losses for investing in this potential dog..
IMO, DYOR.